Diagnos Inc. logo

Diagnos Inc. (ADK)

Market Closed
10 Jun, 20:00
NEO-L NEO-L
CA$
0. 20
-0.03
-14.8936%
CA$
- Market Cap
- P/E Ratio
- Div Yield
5,475 Volume
0 Eps
CA$ 0.23
Previous Close
Add Transaction
Day Range
0.2 0.2
Year Range
0.18 0.4
Want to track ADK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ADK closed Wednesday lower at CA$0.2, a decrease of -14.8936% from Tuesday's close, completing a monthly decrease of -13.0435% or -CA$0.03. Over the past 12 months, ADK stock lost -45.9459%.
ADK is not paying dividends to its shareholders.
The last earnings report, released on May 26, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0033%, based on the last three reports.
Diagnos Inc. has completed 2 stock splits, with the recent split occurring on Apr 24, 2019.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).

ADK Chart

Diagnos Inc. (ADK) FAQ

What is the stock price today?

The current price is CA$0.20.

On which exchange is it traded?

Diagnos Inc. is listed on NEO-L.

What is its stock symbol?

The ticker symbol is ADK.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Diagnos Inc. ever had a stock split?

Diagnos Inc. had 2 splits and the recent split was on Apr 24, 2019.

Diagnos Inc. Profile

Insurance Industry
Financials Sector
Mr. Andre Larente CEO
NEO-L Exchange
CA2524423068 ISIN
CA Country
- Employees
24 Apr 2019 Last Dividend
24 Apr 2019 Last Split
- IPO Date

Overview

DIAGNOS Inc. is a dynamic company offering advanced software-based services with a primary focus on the healthcare sector. With a corporate footprint that extends beyond Canada to the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica, DIAGNOS stands as a global entity dedicated to leveraging technology for health improvement. Founded in 1998 and with its headquarters in Brossard, Canada, the company has harnessed the power of data analysis and artificial intelligence to offer cutting-edge solutions. DIAGNOS Inc. is recognized for its innovative approach to medical diagnostics and consulting services, making significant contributions to the fields it operates in.

Products and Services

  • Computer Assisted Retina Analysis (CARA)
  • DIAGNOS Inc.'s flagship product, CARA, is a web-based software tool designed to revolutionize the way healthcare professionals detect diabetic retinopathy. This condition, a major complication of diabetes, can lead to significant visual impairment if not detected and treated in time. CARA supports eye care specialists by offering a platform for the visualization of both normal and pathological changes within the retina, facilitating early detection and management of this disease.

  • Consulting Services
  • Beyond its software offerings, DIAGNOS extends its expertise through a range of consulting services concentrated in data analysis and the application of artificial intelligence. These services are tailored to help businesses and healthcare entities navigate the complexities of data interpretation, decision-making processes, and the implementation of AI-driven solutions. Through personalized consulting, DIAGNOS empowers its clients to achieve their strategic objectives by leveraging the power of advanced analytics and artificial intelligence.

Contact Information

Address: 7005 Taschereau Boulevard, Brossard, QC, Canada, J4Z 1A7
Phone: 450 678 8882